Amgen Inc. (NASDAQ:AMGN) updated its FY16 earnings guidance on Wednesday. The company provided EPS guidance of $11.10-11.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $11.17. The company issued revenue guidance of $22.5-22.8 billion, compared to the consensus revenue estimate of $22.57 billion.
Several brokerages have commented on AMGN. Vetr downgraded Amgen from a hold rating to a sell rating and set a $162.12 price target on the stock. in a report on Tuesday. Robert W. Baird restated a neutral rating and issued a $157.00 price objective on shares of Amgen in a research note on Friday, July 15th. Bank of America Corp. restated a hold rating and issued a $182.00 price objective on shares of Amgen in a research note on Wednesday, July 13th. Jefferies Group restated a buy rating and issued a $187.00 price objective on shares of Amgen in a research note on Wednesday, July 13th. Finally, BMO Capital Markets restated a buy rating and issued a $186.00 price objective on shares of Amgen in a research note on Tuesday, July 12th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $181.19.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 1.80% during mid-day trading on Wednesday, reaching $170.68. The company had a trading volume of 4,189,760 shares. The company has a market cap of $128.22 billion and a price-to-earnings ratio of 18.06. The firm’s 50-day moving average price is $156.46 and its 200 day moving average price is $153.14. Amgen Inc. has a 52-week low of $130.09 and a 52-week high of $181.81.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th will be issued a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.34%. The ex-dividend date of this dividend is Monday, August 15th.
In other Amgen news, EVP Sean E. Harper sold 21,875 shares of the company’s stock in a transaction on Friday, April 29th. The stock was sold at an average price of $157.99, for a total value of $3,456,031.25. Following the transaction, the executive vice president now directly owns 42,248 shares of the company’s stock, valued at approximately $6,674,761.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Baltimore sold 3,312 shares of the company’s stock in a transaction on Friday, April 29th. The shares were sold at an average price of $157.21, for a total value of $520,679.52. Following the completion of the transaction, the director now directly owns 32,350 shares in the company, valued at $5,085,743.50. The disclosure for this sale can be found here.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
